ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline ...

ZVSADelisted Stock   0.15  0.01  6.25%   
About 59% of ZyVersa Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading ZyVersa Therapeutics stock suggests that many investors are alarmed at this time. The current market sentiment, together with ZyVersa Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use ZyVersa Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
ZyVersa Therapeutics reports a Q1 2025 net loss of 2.3M, a 20.2 percent improvement from the previous year. RD expenses decreased by 49.5 percent to 259K, a

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

ZyVersa Therapeutics Fundamental Analysis

We analyze ZyVersa Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ZyVersa Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ZyVersa Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Employees

Number Of Employees Comparative Analysis

ZyVersa Therapeutics is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

ZyVersa Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ZyVersa Therapeutics stock to make a market-neutral strategy. Peer analysis of ZyVersa Therapeutics could also be used in its relative valuation, which is a method of valuing ZyVersa Therapeutics by comparing valuation metrics with similar companies.
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Consideration for investing in ZyVersa Stock

If you are still planning to invest in ZyVersa Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ZyVersa Therapeutics' history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Valuation
Check real value of public entities based on technical and fundamental data